X4 Pharmaceuticals Inc (XFOR) FinancialsXFORX4 Pharmaceuticals Inc

Evaluating the bottom line, X4 Pharmaceuticals Inc maintains a gross margin of 81.64%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -186.13%, while the net margin is -183.48%. These profitability ratios, combined with a Return on Equity (ROE) of -113.08%, provide a clear picture of how effectively XFOR converts its operational activities into shareholder value.

In the context of the broader market, XFOR competes directly with industry leaders such as SABS and PMN. With a market capitalization of $314.31M, it holds a leading position in the sector. When comparing efficiency, XFOR's gross margin of 81.64% stands against SABS's N/A and PMN's N/A. Such benchmarking helps identify whether X4 Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

X4 Pharmaceuticals reported a revenue of $8.81 million for Q2 2026, surpassing expectations by $6.39 million, and has a gross margin of 81.64% for Q2 2026, indicating strong profitability potential despite recent losses.